The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, ...

Co., Inc. (NYSE: MRK) has initiated a pivotal Phase 3 clinical trial, waveLINE-010, to evaluate the efficacy of its investigational drug zilovertamab vedotin in treating patients with previously ...

The company's blockbuster drug Keytruda contributed $29.48 billion in sales in 2024, but the first of its patent expirations begins in 2028.

Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. Further, following the divestment of the ...

India], January 4: Merck Foundation, the philanthropic arm of Merck KGaA Germany, marks ‘World Cancer Day 2025’ together with ...

Merck Foundation and First Ladies of Africa mark World Cancer Day 2025: 194 Oncology Scholarships Provided Across 32 African Countries ...

RAHWAY, N.J. - Merck & Co ., Inc. (NYSE:MRK) has received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for its pneumococcal ...

Monoclonal antibodies, or mAbs, are important tools in medicine. These laboratory-made proteins are widely used in treatments ...

(RTTNews) - Merck & Co Inc. (MRK), Thursday said it has decided to stop the Phase 3 HYPERION study evaluating Winrevair in pulmonary arterial hypertension (PAH). The HYPERION study is designed to ...

One of Jupiter’s biggest moons has the potential to harbour life in a subsurface sea. The nature of its core will provide information about that ocean.

A multi-ancestry genome-wide study of 158,036 people with bipolar disorder and 2,796,499 control individuals identified 298 genomic regions associated with the disease. Variations in 36 genes were ...

The US Food and Drug Administration (FDA) has accepted for priority review a supplemental new drug application (sNDA) for ...